No Data
Jinshi Asia Pharmaceutical: Report for the third quarter of 2024
Some Shareholders Feeling Restless Over Sichuan Goldstone Asia Pharmaceutical Inc.'s (SZSE:300434) P/S Ratio
Sichuan Goldstone (300434.SZ): Does not involve the production of PBO materials
Goldstone Pharmaceuticals (300434.SZ) stated on the investor interaction platform on September 12 that the company is not involved in the production of PBO materials and is currently conducting research and development work on vacuum coating equipment for the surface metallization treatment of PBO materials.
We Think You Can Look Beyond Sichuan Goldstone Asia Pharmaceutical's (SZSE:300434) Lackluster Earnings
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report Summary
Jinshi Asia Pharmaceutical: 2024 Semi-Annual Report
Sichuan Goldstone Asia Pharmaceutical Inc. (SZSE:300434) Not Doing Enough For Some Investors As Its Shares Slump 26%
No Data
